MDM2 and leukemia: Previous studies showed that the status of p53 is a major determinant of therapeutic responsiveness to MDM2 inhibitors in various cancers/leukemia (Kojima et al., 2006; Saddler et al., 2008; Luo et al., 2020; Zhai et al., 2023).